FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3138930992> ?p ?o ?g. }

• W3138930992 abstract "Achondroplasia causes narrowing of the foramen magnum and the spinal canal leading to increased mortality due to cervicomedullary compression in infants and significant morbidity due to spinal stenosis later in adulthood. Vosoritide is a C-natriuretic peptide analogue that has been shown to improve endochondral ossification in children with achondroplasia. The objective of this trial is to evaluate the safety of vosoritide and whether vosoritide can improve the growth of the foramen magnum and spinal canal in children that may require decompression surgery. An Achondroplasia Foramen Magnum Score will be used to identify infants at risk of requiring decompression surgery. This is a 2-year open label randomized controlled trial of vosoritide in infants with achondroplasia ages 0 to ≤12 months. Approximately 20 infants will be randomized 1:1 to either open label once daily subcutaneous vosoritide combined with standard of care or standard of care alone. The primary and secondary aims of the study are to evaluate the safety and efficacy of vosoritide in children with cervicomedullary compression at risk of requiring decompression surgery. The trial will be carried out in specialized skeletal dysplasia treatment centers with well established multidisciplinary care pathways and standardized approaches to the neurosurgical management of cervicomedually compression. After 2 years, infants randomized to standard of care alone will be eligible to switch to vosoritide plus standard of care for an additional 3 years. This pioneering trial hopes to address the important question as to whether treatment with vosoritide at an early age in infants at risk of requiring cervicomedullary decompression surgery is safe, and can improve growth at the foramen magnum and spinal canal alleviating stenosis. This in turn may reduce compression of surrounding structures including the neuraxis and spinal cord, which could alleviate future morbidity and mortality.Trial registrations: ClinicalTrials.gov, NCT04554940; EudraCT number, 2020-001055-40." @default.
• W3138930992 created "2021-03-29" @default.
• W3138930992 creator A5000857707 @default.
• W3138930992 creator A5005489241 @default.
• W3138930992 creator A5017618566 @default.
• W3138930992 creator A5018113243 @default.
• W3138930992 creator A5026606066 @default.
• W3138930992 creator A5029071712 @default.
• W3138930992 creator A5030157085 @default.
• W3138930992 creator A5049116457 @default.
• W3138930992 creator A5060164558 @default.
• W3138930992 creator A5061306814 @default.
• W3138930992 creator A5068476552 @default.
• W3138930992 creator A5068521712 @default.
• W3138930992 creator A5079820652 @default.
• W3138930992 date "2021-01-01" @default.
• W3138930992 modified "2023-09-27" @default.
• W3138930992 title "Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgery" @default.
• W3138930992 cites W1581599228 @default.
• W3138930992 cites W1597997618 @default.
• W3138930992 cites W1599248800 @default.
• W3138930992 cites W1689560426 @default.
• W3138930992 cites W1917939628 @default.
• W3138930992 cites W1972845920 @default.
• W3138930992 cites W2019506838 @default.
• W3138930992 cites W2034041551 @default.
• W3138930992 cites W2036291263 @default.
• W3138930992 cites W2048093713 @default.
• W3138930992 cites W2060682345 @default.
• W3138930992 cites W2077727595 @default.
• W3138930992 cites W2080349051 @default.
• W3138930992 cites W2093976981 @default.
• W3138930992 cites W2103051141 @default.
• W3138930992 cites W2137579812 @default.
• W3138930992 cites W2145821846 @default.
• W3138930992 cites W2148435694 @default.
• W3138930992 cites W2150597242 @default.
• W3138930992 cites W2154917734 @default.
• W3138930992 cites W2158317138 @default.
• W3138930992 cites W2160121475 @default.
• W3138930992 cites W2224249618 @default.
• W3138930992 cites W2233738694 @default.
• W3138930992 cites W2681663353 @default.
• W3138930992 cites W2805260791 @default.
• W3138930992 cites W2912439926 @default.
• W3138930992 cites W2947905904 @default.
• W3138930992 cites W2950774550 @default.
• W3138930992 cites W2959698893 @default.
• W3138930992 cites W2999797567 @default.
• W3138930992 cites W3048406954 @default.
• W3138930992 cites W3081737776 @default.
• W3138930992 cites W3082819488 @default.
• W3138930992 cites W4211105381 @default.
• W3138930992 doi "https://doi.org/10.1177/00368504211003782" @default.
• W3138930992 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33761804" @default.
• W3138930992 hasPublicationYear "2021" @default.
• W3138930992 type Work @default.
• W3138930992 sameAs 3138930992 @default.
• W3138930992 citedByCount "11" @default.
• W3138930992 countsByYear W31389309922021 @default.
• W3138930992 countsByYear W31389309922022 @default.
• W3138930992 countsByYear W31389309922023 @default.
• W3138930992 crossrefType "journal-article" @default.
• W3138930992 hasAuthorship W3138930992A5000857707 @default.
• W3138930992 hasAuthorship W3138930992A5005489241 @default.
• W3138930992 hasAuthorship W3138930992A5017618566 @default.
• W3138930992 hasAuthorship W3138930992A5018113243 @default.
• W3138930992 hasAuthorship W3138930992A5026606066 @default.
• W3138930992 hasAuthorship W3138930992A5029071712 @default.
• W3138930992 hasAuthorship W3138930992A5030157085 @default.
• W3138930992 hasAuthorship W3138930992A5049116457 @default.
• W3138930992 hasAuthorship W3138930992A5060164558 @default.
• W3138930992 hasAuthorship W3138930992A5061306814 @default.
• W3138930992 hasAuthorship W3138930992A5068476552 @default.
• W3138930992 hasAuthorship W3138930992A5068521712 @default.
• W3138930992 hasAuthorship W3138930992A5079820652 @default.
• W3138930992 hasBestOaLocation W31389309921 @default.
• W3138930992 hasConcept C118552586 @default.
• W3138930992 hasConcept C141071460 @default.
• W3138930992 hasConcept C168563851 @default.
• W3138930992 hasConcept C187212893 @default.
• W3138930992 hasConcept C2776106272 @default.
• W3138930992 hasConcept C2779326565 @default.
• W3138930992 hasConcept C2779480328 @default.
• W3138930992 hasConcept C2780472190 @default.
• W3138930992 hasConcept C2780775167 @default.
• W3138930992 hasConcept C71924100 @default.
• W3138930992 hasConceptScore W3138930992C118552586 @default.
• W3138930992 hasConceptScore W3138930992C141071460 @default.
• W3138930992 hasConceptScore W3138930992C168563851 @default.
• W3138930992 hasConceptScore W3138930992C187212893 @default.
• W3138930992 hasConceptScore W3138930992C2776106272 @default.
• W3138930992 hasConceptScore W3138930992C2779326565 @default.
• W3138930992 hasConceptScore W3138930992C2779480328 @default.
• W3138930992 hasConceptScore W3138930992C2780472190 @default.
• W3138930992 hasConceptScore W3138930992C2780775167 @default.
• W3138930992 hasConceptScore W3138930992C71924100 @default.
• W3138930992 hasFunder F4320310557 @default.
• W3138930992 hasIssue "1" @default.
• W3138930992 hasLocation W31389309921 @default.

• next